Indian Journal of Pharmacology Home 

CLINICAL RESEARCH ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2020  |  Volume : 52  |  Issue : 2  |  Page : 79--85

Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study

Renuka L Kadam1, Smita Dipak Sontakke1, Prashant Tiple2, Vijay M Motghare1, Chaitali S Bajait1, Mrunalini V Kalikar1 
1 Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India
2 Department of Psychiatry, Government Medical College, Nagpur, Maharashtra, India

Correspondence Address:
Smita Dipak Sontakke
502, Silver Palms, Q.9 Laxminagar, Nagpur - 440 022, Maharashtra
India

OBJECTIVES: To evaluate and compare efficacy and tolerability of Vilazodone with Escitalopram and Amitriptyline in patients of major depressive disorder(MDD). METHODS: This was a randomized, prospective, parallel-group, open label clinical study in which newly diagnosed patients of MDD were randomized to receive Tab Vilazodone 20 mg daily or Tab Escitalopram 20mg daily or Tab Amitriptyline 75mg daily for 12 weeks. Antidepressant activity was assessed by change in score from baseline to week 12 on HAMD-17 and MADRS scales while change in score on HAM-A scale was used to assess antianxiety effect. Change in scores on the three scales was also compared between the three treatment groups. Severity and causality of adverse events were assessed by the modified Hartwig & Siegel scale and Naranjo scale respectively. Data was analyzed in accordance with per protocol analysis. RESULTS: Reduction in HAMD-17 and MADRS scores was significantly more in vilazodone group compared to the other two drugs indicating that vilazodone is more efficacious antidepressant. Number of remitters were also significantly more in the vilazodone group (n=11) compared to escitalopram (n=4) (p <0.05) and amitriptyline (n=0) (p <0.001) at 12 weeks. Similar results were also obtained with HAM-A score. Number of patients showing MADRS sustained response at 12 weeks was statistically significantly more in vilazodone (n=12) and escitalopram (n=12) groups compared to amitriptyline (n=01) (p <0.001). Reported adverse events were constipation and sedation(amitriptyline group); nausea and headache(escitalopram and vilazodone groups). These adverse events were of mild severity. Most adverse events belonged to probable category. CONCLUSION: Vilazodone is more efficacious and well tolerated antidepressant compared to escitalopram and amitriptyline.


How to cite this article:
Kadam RL, Sontakke SD, Tiple P, Motghare VM, Bajait CS, Kalikar MV. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study.Indian J Pharmacol 2020;52:79-85


How to cite this URL:
Kadam RL, Sontakke SD, Tiple P, Motghare VM, Bajait CS, Kalikar MV. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study. Indian J Pharmacol [serial online] 2020 [cited 2020 Jul 7 ];52:79-85
Available from: http://www.ijp-online.com/article.asp?issn=0253-7613;year=2020;volume=52;issue=2;spage=79;epage=85;aulast=Kadam;type=0